Advertisement

Search Results

Advertisement



No results found for "*,*"

Suggestions:

  • Ensure words are spelled correctly.
  • Try rephrasing keywords or using synonyms.
  • Try less specific keywords.
Advertisement

Advertisement




Nov
13
Today In Oncology
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
FDA Approves Ziftomenib for NMP1-Positive AML
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers
Advanced Epithelial Ovarian Cancer First-Line PARP Inhibitor Maintenance Therapy and Survival
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo